Vaxil Bio Ltd. (VXL.V) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+136.7%

CA$0.24

vs CA$0.10 price

Levered DCF

CA$0.24

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-14.16

Distress zone

Rating

—

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	0.81×	-157.69×	-12.5×	-232.56×	-520.83×	-1,111.11×	-133.59×	-121.95×
P/B	0.3×	39.22×	192.17×	120.58×	300.23×	1,898.08×	-266.94×	293.58×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	1.45×	-921.09×	-675.73×	-232.76×	-528.76×	-1,181.82×	-149.15×	-128.89×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	137×	43.12×	11.48×	3.8×	3.9×	1.91×	0.14×	1.82×
Debt / equity	0×	0×	0×	0×	0×	0.01×	-0.03×	0.01×
Interest coverage	0×	0×	0×	0×	0×	-122.45×	-103.91×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	38.2%	-24.9%	-0.0%	-51.4%	-58.0%	-168.9%	199.8%	-240.7%
Return on invested capital	-13.1%	-27.4%	-28.5%	-51.4%	-58.0%	-165.7%	190.8%	-236.6%
Return on assets	38.1%	-24.3%	-0.0%	-37.9%	-43.2%	-81.8%	-568.3%	-117.6%
Free cash flow yield	-41.4%	-0.9%	-0.3%	-0.5%	-0.2%	-0.1%	-0.4%	-0.7%
Earnings yield	127.0%	-0.6%	-0.0%	-0.4%	-0.2%	-0.1%	-0.7%	-0.8%
Enterprise value	-CA$259.9K	CA$27.6M	CA$170.3M	CA$135.5M	CA$508.1M	CA$1.5B	CA$155.6M	CA$127M
Net debt / EBITDA	3.75×	14.93×	3.72×	2.59×	2.33×	1.16×	0.06×	0.76×
Cash conversion cycle (days)	0	0	0	-71,905	-8,161	-3,765	-1,719	-2,183